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Key Points
Question
Do major depressive disorder and alcohol dependence share common genetic risk variants?
Findings
In this cohort study of 4 independent samples of 3871 individuals with alcohol dependence and 3347
individuals serving as controls, elevated polygenic risk for major depressive disorder also conveyed a
significant increase in risk for alcohol dependence.
Meaning
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Major depressive disorder (MDD) and alcohol dependence (AD) are heritable disorders with significant
public health burdens, and they are frequently comorbid. Common genetic factors that influence the co-
occurrence of MDD and AD have been sought in family, twin, and adoption studies, and results to date
have been promising but inconclusive.
Objective
To examine whether AD and MDD overlap genetically, using a polygenic score approach.
Design, Settings, and Participants
Association analyses were conducted between MDD polygenic risk score (PRS) and AD case-control status
in European ancestry samples from 4 independent genome-wide association study (GWAS) data sets: the
Collaborative Study on the Genetics of Alcoholism (COGA); the Study of Addiction, Genetics, and
Environment (SAGE); the Yale-Penn genetic study of substance dependence; and the National Health and
Resilience in Veterans Study (NHRVS). Results from a meta-analysis of MDD (9240 patients with MDD
and 9519 controls) from the Psychiatric Genomics Consortium were applied to calculate PRS at thresholds
from P < .05 to P ≤ .99 in each AD GWAS data set.
Main Outcomes and Measures
Association between MDD PRS and AD.
Results
Participants analyzed included 788 cases (548 [69.5%] men; mean [SD] age, 38.2 [10.8] years) and 522
controls (151 [28.9.%] men; age [SD], 43.9 [11.6] years) from COGA; 631 cases (333 [52.8%] men; age
[SD], 35.0 [7.7] years) and 756 controls (260 [34.4%] male; age [SD] 36.1 [7.7] years) from SAGE; 2135
cases (1375 [64.4%] men; age [SD], 39.4 [11.5] years) and 350 controls (126 [36.0%] men; age [SD], 43.5
[13.9] years) from Yale-Penn; and 317 cases (295 [93.1%] men; age [SD], 59.1 [13.1] years) and 1719
controls (1545 [89.9%] men; age [SD], 64.5 [13.3] years) from NHRVS. Higher MDD PRS was associated
with a significantly increased risk of AD in all samples (COGA: best P = 1.7 × 10 , R  = 0.026; SAGE:
best P = .001, R  = 0.01; Yale-Penn: best P = .035, R  = 0.0018; and NHRVS: best P = .004, R  = 0.0074),
with stronger evidence for association after meta-analysis of the 4 samples (best P = 3.3 × 10 ). In
analyses adjusted for MDD status in 3 AD GWAS data sets, similar patterns of association were observed
(COGA: best P = 7.6 × 10 , R  = 0.023; Yale-Penn: best P = .08, R  = 0.0013; and NHRVS: best P = .006,
R  = 0.0072). After recalculating MDD PRS using MDD GWAS data sets without comorbid MDD-AD
cases, significant evidence was observed for an association between the MDD PRS and AD in the meta-
analysis of 3 GWAS AD samples without MDD cases (best P = .007).
Conclusions and Relevance
These results suggest that shared genetic susceptibility contributes modestly to MDD and AD comorbidity.
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Introduction
The association between alcohol dependence (AD) and major depressive disorder (MDD) has been studied
by clinicians, epidemiologists, and geneticists for more than 100 years. Bleuler and Brill described
“alcoholic melancholia,” characterized by brief periods of depression after alcohol binges, which could
precipitate a suicide attempt. States of depressed mood associated with both alcohol use and withdrawal
were documented by later researchers, while others noted that some individuals who increased their
drinking during periods of depression tended to progress to AD.
More recently, the rate of AD and MDD comorbidity was assessed in cross-sectional epidemiologic studies.
The National Comorbidity Study linked AD to 3.7-fold higher odds of experiencing a major depressive
episode in the prior year. In the 2012-2013 National Epidemiologic Survey on Alcoholism and Related
Conditions, individuals with a lifetime diagnosis of MDD had a 1.3-fold increased risk of an alcohol use
disorder. Furthermore, both the National Comorbidity Study and Epidemiological Catchment Area study
found that AD worsened the symptoms of MDD and vice versa, which may explain why people with
comorbid AD and MDD are at greater risk for suicide.
This pattern of comorbidity has prompted hypotheses regarding causal relationships between AD and
MDD. One hypothesis is that AD causes MDD either directly, through alcohol’s pharmacologic effects on
the brain, or indirectly, through negative social consequences that increase the risk of MDD. A second
hypothesis is that MDD can lead to AD. Longitudinal studies support an internalizing pathway from MDD
to AD, with some individuals using alcohol to self-medicate negative mood states.
A third hypothesis, that shared genetic factors predispose to both AD and MDD, has had mixed support. A
longitudinal study of Finnish twins showed a shared genetic liability between alcohol use and depressive
symptoms across adolescence. Researchers from the Collaborative Study on the Genetics of Alcoholism
(COGA) reported aggregation of MDD in relatives of probands with AD, whether or not the proband had
MDD or the relative had AD. Other family studies have also suggested a genetic link between AD and
MDD, including both sex-specific effects and environmental influences on their comorbidity.
Molecular genetic studies have implicated specific genomic regions and genes for both AD and MDD risk.
Linkage analysis by COGA identified a region on chromosome 1 associated with both MDD and AD.
Candidate gene studies reported a number of genes possibly underlying both disorders, including CHRM2,
SLC6A4, COMT, and DRD2, although other studies failed to replicate these associations. Genome-wide
association studies (GWASs) have produced significant findings for both AD and MDD, although not for
comorbid AD-MDD.
In the present study, we examined whether AD and MDD overlap genetically using polygenic risk scores
(PRSs), which are quantitative measures of the cumulative effects of common genetic variations across the
genome on risk for a disorder. Using PRSs derived from a Psychiatric Genomics Consortium (PGC) meta-
analysis of MDD, we tested whether PRSs for MDD were associated with AD case-control status in
samples from 4 independent GWAS data sets: (1) COGA; (2) the Study of Addiction, Genetics, and
Environment (SAGE); (3) the Yale-Penn genetic study of substance dependence; and (4) the National
Health and Resilience in Veterans Study (NHRVS).
Methods
AD GWAS Data Sets
Basic information on the AD GWAS data sets is summarized in Table 1. All participants in the COGA,
Yale-Penn, and NHRVS studies gave informed consent for participation, and all procedures and protocols
used in each sample were approved by the institutional review board at the relevant institution. Participants
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received financial compensation. COGA involved multiple centers in the United States: Indiana University;
State University of New York Health Science Center, Brooklyn; University of Connecticut; University of
Iowa; University of California, San Diego; Washington University; and Howard University. The
institutional review boards of all of these participating institutions approved the study. The Yale-Penn study
was approved by the Yale University Human Investigation Committee. The NHRVS procedures were
approved by the human subjects subcommittee of the Veterans Affairs (VA) Connecticut Healthcare System
and the VA Office of Research and Development.
Samples were drawn from an ongoing, family-based study of AD including participants from 6 sites
across the United States. Patient cases had a lifetime diagnosis of AD by DSM-IV criteria. Individuals
serving as controls had consumed alcohol but did not meet criteria for AD, alcohol abuse, or other
substance use disorders in their lifetime. A sample of 1945 participants from COGA was genotyped
(Illumina Human1M microarray; Illumina). After data quality control, 1310 European American
individuals (788 with AD and 522 controls) were included.
Samples were selected from 3 studies: COGA, the Family Study of Cocaine Dependence, and the
Collaborative Genetic Study of Nicotine Dependence. Full details are available elsewhere. Alcohol
dependence was defined based on DSM-IV criteria. Controls were individuals without a lifetime diagnosis
of dependence on any substance. A total of 4316 samples were genotyped (Illumina Human1M
microarray). After quality control and excluding participants overlapping with COGA, 1387 European
American individuals (631 with AD and 756 controls) were retained for analysis.
The Yale-Penn samples included individuals recruited for genetic studies of cocaine
dependence, opioid dependence, and AD, as described previously. Alcohol dependence was defined using
DSM-IV criteria. Control participants did not meet the DSM-IV criteria for lifetime AD or other substance
use disorders. DNA samples from 9459 individuals were genotyped using 1 of 2 platforms: (1) the Illumina
HumanOmni1 Quad, version 1.0 microarray containing 988 306 autosomal single-nucleotide
polymorphisms (SNPs) or (2) the Illumina Infinium Human Core Exome microarray, containing 265 919
exome-focused SNPs and approximately 240 000 tagging SNPs. Genome-wide association studies quality
control and imputation were conducted for the merged GWAS samples based on a common set of
autosomal SNPs (230 447). After quality control, the final analysis included 2485 European American
individuals (2135 with AD and 350 controls).
The NHRVS data set included US military veterans who participated in a nationally representative
cohort study in 2011. Alcohol dependence was assessed according to DSM-IV diagnostic criteria. Controls
were defined as individuals without lifetime AD or other substance dependence. A total of 2825 samples
were genotyped with the Infinium PsychArray, version 1.1. After quality control, 2036 European American
individuals (317 AD and 1719 controls) were retained for analysis.
GWAS Quality Control
Each GWAS data set was cleaned via PLINK, version 1.07 before analysis. Samples and SNPs were
excluded based on predetermined quality control metrics, including sample call rate of 95% or less, SNP
call rate of 95% or less, minor allele frequency of 0.01 or less in controls, and P values for Hardy-Weinberg
equilibrium tests ≤10  for controls. We estimated the genome-wide identity by descent sharing between all
pairs of participants to detect duplicates (individuals genotyped twice within 1 sample or individuals in 1
sample also included in another) and then randomly removed 1 duplicate from each pair. We used
EIGENSOFT, version 6.1.3 to compute principal components for each GWAS data set using pruned SNPs
in low linkage disequilibrium (r <0.2). Outliers, defined as participants with ancestry at least 3 SDs from
the mean on 1 of the 2 largest principal components, were removed. After quality control, there were 843 
188 (COGA), 837 142 (SAGE), 220 554 (Yale-Penn), and 287 923 (NHRVS) autosomal SNPs retained. To
−6
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ensure that sample overlap did not contribute to inflated estimates of genetic overlap between AD and
MDD, λ meta statistics were calculated. The λ meta is a statistic that uses effect size concordance to detect
sample overlap or heterogeneity. All λ meta values were larger than 1 (1.02<λ meta <1.06), indicating no
significant overlap between AD and PGC MDD samples.
Imputation
Following the best practice guidelines of IMPUTE2, version 2.3.2, we imputed 1000 Genomes variants into
each GWAS sample. Prephasing was first performed with SHAPEIT, version 2.790 to infer haplotypes for
samples based on autosomal SNPs with minor allele frequency greater than 0.01. Imputation was carried
out on prephased haplotypes using IMPUTE2 against reference data from the 1000 Genomes Phase 1
integrated variant set for all GWAS data except for the NHRVS and Yale-Penn samples, which were
imputed against the 1000 Genomes Phase 3 haplotype reference. After postimputation (SNP missing rate
<0.05, minor allele frequency >0.05, imputation quality score >0.5, and Hardy-Weinberg equilibrium
>10 ), 5 960 232 (COGA), 5 955 937 (SAGE), 7 049 271 (Yale-Penn), and 7 055 726 (NHRVS) autosomal
variants were retained. Imputed SNPs were used for calculating the PRS, as described below.
Polygenic Score Analysis
Each PRS was calculated as a weighted sum of reference alleles across independent SNPs on a genome-
wide scale. Weights were log  (odds ratio) of SNPs estimated from a meta-analysis of MDD GWASs
(9240 MDD cases and 9519 controls of European ancestry) from the PGC. Summary results for 1 235 109
autosomal SNPs were downloaded from the PGC website (https://www.med.unc.edu/pgc/). Downloaded
SNPs were pruned using P value–informed clumping in PLINK, with a cutoff of r  = 0.2 within a 200-
kilobase window. Polygenic risk scores were calculated for each AD GWAS sample using the PLINK score
option, based on sets of pruned SNPs at successive P value thresholds (<.05 to ≤.99).
We used GEMMA, version 0.96 software to evaluate associations between the PRS and AD in a mixed-
model framework accounting for related samples and cryptic relationships. Association analyses were
corrected for age, sex, and the top 10 principal components to control for population stratification. Each
PRS was scaled from 0 to 2 so that association strength was comparable across GWAS data sets and P
value thresholds. To combine association evidence across samples, we carried out meta-analysis based on
effect size and SE using METAL. The portion of the variance in AD case-control status explained by the
PRS was assessed by the Nagelkerke pseudo R , which was derived from the difference between the
maximum likelihood of the null model (principal components + covariates) and the full model (principal
components + covariates + PRSs).
We conducted 2 additional analyses to further evaluate bidirectional relationships between MDD and AD:
(1) to determine whether the association of the PRS with AD was driven by comorbid MDD cases in AD
GWAS data sets, we repeated the analyses adjusting for MDD status in the 3 AD GWAS data sets (COGA,
NHRVS, and Yale-Penn) for which MDD status was available; and (2) to examine whether the association
of the PRS with AD was driven by comorbid AD cases in MDD PGC data sets, we recalculated the MDD
PRS for AD GWAS data sets using weights from meta-analysis of 2 MDD GWAS data sets (Genetics of
Recurrent Early-Onset Depression [GenRED]-I, 860 MDD cases and 1636 controls; and GenRED-II, 1145
MDD cases and 930 controls) for which comorbid MDD-AD cases could be excluded. Details of GenRED
GWASs are available elsewhere. Both data sets were imputed into 1000 Genomes Phase 3 variants using
imputation procedures described above. GEMMA was used for association testing of MDD with each SNP,
followed by meta-analysis of the 2 imputed data sets using METAL. Meta-analysis results were used to
recalculate the PRS for each AD GWAS data set. We then performed association tests between recalculated
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MDD cases.
Positive and Negative Controls
We tested the ability of the PGC-derived MDD PRS to predict MDD status in 3 AD GWAS data sets
(COGA, NHRVS, and Yale-Penn) for which MDD status was available as a positive control. Height was
similarly tested as a negative control in the same samples.
Results
Basic sample demographics are reported in Table 1. In the COGA sample, 18.9% of individuals with AD
had MDD and 12.5% of controls had MDD. In the Yale-Penn sample, 19.4% of those with AD had MDD
and 6.3% of controls had MDD. The NHRVS sample had the highest rate of comorbid MDD, with 35.0%
in AD cases; the MDD rate in controls was 10.5%. Major depressive disorder status was unavailable for
SAGE.
We observed significant associations between the MDD PRS and AD case-control status across all AD
samples at various PRS P value thresholds (COGA: best P = 1.7 × 10 , R  = 0.026; SAGE: best P = .001,
R  = 0.01; Yale-Penn: best P = .035, R  = 0.0018; NHRVS: best P = .004, R  = 0.0074) (eTable 1 in the
Supplement). Meta-analysis of the 4 AD samples showed stronger evidence for association with the
smallest value (P = 3.3 × 10 ; P value threshold = .4) (Table 2). Regression coefficients (β) were positive
at each PRS P value threshold, suggesting that an elevated MDD PRS is linked to an increased risk of AD.
However, the proportion of variance in AD explained by the MDD PRS was small, ranging from R  = 
0.0018 in the Yale-Penn sample to R  = 0.026 in the COGA sample (eTable 1 in the Supplement and Figure
). To investigate potential sex-specific effects, the same analyses were repeated stratified by sex. No
consistent difference in the strength or significance of association between MDD PRSs and AD status by
sex was observed across the 4 samples (eTable 2 and eFigure in the Supplement).
We observed similar patterns of association between the MDD PRSs and AD case-control status when
MDD status was included as a covariate (COGA: best P = 7.6 × 10 , R  = 0.023; Yale-Penn: best P = .08,
R  = 0.0013; and NHRVS: best P = .006, R  = 0.0072) (eTable 3 in the Supplement). Meta-analysis of the 3
samples strengthened evidence of association with the smallest P = 2.5 × 10  (P value threshold = .50) (
Table 2). The proportion of variance in AD explained by the MDD PRS was nearly identical to that of the
unadjusted analyses in the corresponding samples.
We recalculated the MDD PRSs for AD GWAS samples using weights derived from 2 MDD GWAS data
sets in which comorbid MDD-AD cases were excluded. We then tested the new MDD PRSs with AD case-
control status in 3 AD GWAS samples without MDD cases. The new MDD PRS was nominally
significantly associated with AD in the COGA sample at a PRS P value threshold of 0.05 (P = .04) (eTable
4 in the Supplement). We did not observe significant evidence for association in the Yale-Penn and NHRVS
samples, although the new MDD PRSs tended to increase AD risk across both samples. Meta-analysis of
the 3 AD samples yielded significant evidence for association between the MDD PRS and AD with the
smallest P = .007 (PRS P value threshold = .20 or .05) (eTable 5 in the Supplement).
We tested whether the MDD PRS would predict MDD status as a positive control. A significant association
was seen in the Yale-Penn sample (7.6 × 10 ≤P ≤ .004) but not in either COGA or NHRVS, although a
trend toward increased MDD risk was observed in both samples (eTable 6 in the Supplement). In a meta-
analysis, significant associations were seen at all thresholds (2.5 × 10 ≤P ≤ .05) (eTable 7 in the
Supplement). Height, our negative control, showed no significant association with the MDD PRS in any
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Discussion
In each independent AD GWAS sample, we found that a higher MDD PRS was associated with an
increased risk for AD, and this result was even more pronounced in a meta-analysis of the 4 data sets. The
same effect was seen in analyses with MDD status as a covariate in 3 AD GWAS samples. We also
observed meta-analytic evidence for an association between MDD PRSs and AD, using a PRS derived
from MDD GWAS data sets without comorbid MDD-AD cases. Our results suggest that the bidirectional
associations between AD and MDD may be partially accounted for by shared genetic factors.
Our study methodology is similar to that of other published studies examining the association between AD
genetic risk and AD age of onset; between childhood trauma, MDD genetic risk, and adult MDD; and
between schizophrenia genetic risk and cannabis use. Consistent with those studies, the proportion of
variance in AD explained by the MDD PRS in our samples was small, on the order of 10  to 10 . Similar
effect sizes were seen in our positive control, MDD status.
Although our results do not illuminate the mechanism by which this shared genetic liability for MDD and
AD acts, several possibilities are worth investigating in future studies. Anxiety disorders and MDD share
genetic liability, and anxiety has been proposed as a significant risk factor linking AD and MDD via the
internalizing pathway. More broadly, personality traits, such as neuroticism, disinhibition, and sensation-
seeking, are associated with a range of psychiatric disorders, including anxiety, MDD, and AD, and are
potential mechanisms through which shared AD-MDD polygenic risk may exert its effects. Inclusion of
comorbid disorders and personality trait measures in future studies may help to clarify these pathways.
The PGC MDD GWAS samples are likely enriched for individuals with AD, which could drive the
associations initially observed between MDD PRSs and AD. To examine this possibility, we recalculated
the MDD PRS using 2 MDD GWAS data sets without comorbid MDD-AD cases and tested the association
of the new PRS with AD in AD GWAS samples without MDD cases. We observed a significant association
between this recalculated MDD PRS and AD status only in the COGA sample at a threshold of P < .05 (P 
= .04), potentially due to the smaller sample size of this training data set. Nonetheless, meta-analysis of all
samples showed significant associations between the recalculated MDD PRS and AD, suggesting that the
observed associations are not driven solely by comorbid AD cases in the PGC MDD GWAS and providing
further support for genetic overlap between MDD and AD.
Prior family and twin studies suggested a role for sex-specific transmission of shared AD-MDD risk. In
post hoc analyses, we examined sex-specific patterns of association between MDD PRSs and AD risk. We
did not find consistent evidence of sex-specific transmission of shared AD-MDD liability in sex-stratified
analyses, although our study was likely underpowered to detect such an effect given the reduced sample
sizes in sex-specific subgroups.
Limitations
This work should be viewed in light of 2 limitations. First, MDD GWASs with larger sample sizes will
likely improve the predictive ability of the MDD PRS and thus further refine the associations that we
observed. Second, further studies are needed to investigate whether the MDD PRS association is specific to
AD or whether it generalizes to substance dependence more broadly. There is evidence that a large
proportion of genetic risk for substance use disorders involves predisposition to addiction generally, and
some data have demonstrated that PRSs for psychopathology predict general substance involvement.
Conclusions
From a public health standpoint, MDD and AD are individually and jointly associated with significant
morbidity and mortality, so understanding their association is a priority. Our findings suggest that common
−2 −3
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genetic factors contribute to MDD-AD comorbidity and that some individuals carry a genetic
predisposition for both disorders. The consistency of our findings across 4 independent samples suggests
the feasibility and value of a meta-analysis of AD and MDD GWAS data sets to identify specific genetic
variations underlying this shared predisposition.
Notes
Supplement.
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eTable 2. Associations Between MDD Polygenic Risk Scores and AD Stratified by Sex
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COGA SAGE Yale-Penn NHRVS
AD 788 631 2135 317
Men 548 (69.5) 333 (52.8) 1375 (64.4) 295 (93.1)
Age, mean (SD), y 38.2 (10.8) 35.0 (7.7) 39.4 (11.5) 59.1 (13.1)
MDD 149 (18.9) NA 414 (19.4) 111 (35.0)
Controls 522 756 350 1719
Men 151 (28.9) 260 (34.4) 126 (36.0) 1545 (89.9)
Age, mean (SD), y 43.9 (11.6) 36.1 (7.7) 43.5 (13.9) 64.5 (13.3)
MDD 65 (12.5) NA 22 (6.3) 180 (10.5)
Abbreviations: AD, alcohol dependence; COGA, Collaborative Study on the Genetics of Alcoholism; MDD, major
depressive disorder; NA, not available; NHRVS, National Health and Resilience in Veterans Study; SAGE, Study of
Addiction, Genetics, and Environment.
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Table 2.
Meta-analysis of Associations Between MDD Polygenic Risk Scores and AD
Thresholds Adjusting for MDD in AD Samples
No Yes
β SE P Value β SE P Value
P < .05 0.075 0.016 2.8 × 10 0.064 0.017 1.3 × 10
P < .10 0.075 0.016 3.1 × 10 0.061 0.017 2.5 × 10
P < .20 0.084 0.016 1.0 × 10 0.070 0.017 2.0 × 10
P < .30 0.088 0.016 2.6 × 10 0.074 0.017 8.4 × 10
P < .40 0.095 0.016 3.3 × 10 0.079 0.017 3.3 × 10
P < .50 0.094 0.016 3.5 × 10 0.080 0.017 2.5 × 10
P < .60 0.094 0.016 4.2 × 10 0.079 0.017 3.4 × 10
P < .70 0.095 0.016 3.8 × 10 0.079 0.017 3.2 × 10
P < .80 0.093 0.016 6.5 × 10 0.078 0.017 4.4 × 10
P < .90 0.094 0.016 5.3 × 10 0.079 0.017 3.7 × 10
P ≤ .99 0.094 0.016 5.3 × 10 0.079 0.017 3.7 × 10
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Figure.
Association of the Major Depressive Disorder Polygenic Risk Score With Alcohol Dependence (AD) in 4
Independent Samples
The y-axis presents the Nagelkerke pseudo R  that indicates the variance explained in AD for each P value threshold
shown. P values given represent the strongest association observed in each sample. COGA indicates Collaborative Study
on the Genetics of Alcoholism; NHRVS, National Health and Resilience in Veterans Study; and SAGE, Study of
Addiction, Genetics, and Environment.
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